AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33262189 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin as add-on to escitalopram
Number of subjects: 160
Study 33262189 — intervention group
Group type: COMPARATOR
Intervention: Placebo as add-on to escitalopram
Number of subjects: 160
Study 35904459 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 234
Study 35904459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study 34948523 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week web-based parent-child physical activity program
Number of subjects: 75
Study 34948523 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study 36055668 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Fibrin (PRF) application
Number of subjects: 40
Study 36055668 — intervention group
Group type: COMPARATOR
Intervention: Control group (without PRF application)
Number of subjects: 40
Study 33596735 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily tenofovir/emtricitabine (TDF-FTC)
Number of subjects: 678
Study 36150526 — intervention group
Group type: EXPERIMENTAL
Intervention: Obeticholic Acid (OCA)
Number of subjects: 209
Study 36150526 — intervention group
Group type: COMPARATOR
Intervention: Control (Global PBC)
Number of subjects: 209
Study 36150526 — intervention group
Group type: COMPARATOR
Intervention: Control (UK-PBC)
Number of subjects: 209
Study 33468520 — intervention group
Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 0
Study 33468520 — intervention group
Group type: COMPARATOR
Intervention: Prior GLP‐1 RA
Number of subjects: 0
Study 33444208 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (600 mg just before surgery and 600 mg/day for 2 days after surgery)
Number of subjects: 0
Study 33444208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35510611 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTIVE cognitive training (memory, reasoning, and speed of processing)
Number of subjects: 2802
Study 35510611 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline cognition
Number of subjects: 2802
Study 34551412 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental screening plus referral to a specific treating facility (intervention arm)
Number of subjects: 1098
Study 34551412 — intervention group
Group type: COMPARATOR
Intervention: Screening plus advice letter to see a dentist (control arm)
Number of subjects: 1098
Study 36172665 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based palliative care (three-month home visit)
Number of subjects: 50
Study 36172665 — intervention group
Group type: COMPARATOR
Intervention: Control group (no palliative care)
Number of subjects: 50
Study 33541378 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower extremity manipulation
Number of subjects: 0
Study 33541378 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper extremity manipulation
Number of subjects: 0
Study 33541378 — intervention group
Group type: COMPARATOR
Intervention: Control (no manipulation)
Number of subjects: 0
Study 36013230 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanita mental health literacy educational programme (three 50-min classes)
Number of subjects: 125
Study 36013230 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 125
Study 33043552 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (5 mg daily for 2 weeks)
Number of subjects: 19
Study 33043552 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (up to 10 mg daily in open-label extension)
Number of subjects: 19
Study 33043552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 34387038 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.2 mg orally once at night for 3 days starting on postoperative day 1 (treatment group)
Number of subjects: 95
Study 34387038 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment (control group)
Number of subjects: 95
Study 32096613 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/day SC elamipretide for 4 weeks
Number of subjects: 30
Study 32096613 — intervention group
Group type: COMPARATOR
Intervention: Placebo SC for 4 weeks
Number of subjects: 30
Study 32096613 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/day SC elamipretide
Number of subjects: 30
Study 34999923 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley catheter and controlled release dinoprostone
Number of subjects: 203
Study 34999923 — intervention group
Group type: COMPARATOR
Intervention: Foley catheter alone
Number of subjects: 203
Study 33872573 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative Pressure Massage Treatment (NPMT)
Number of subjects: 28
Study 33872573 — intervention group
Group type: COMPARATOR
Intervention: Manual Lymphatic Drainage (MLD)
Number of subjects: 28
Study 35338860 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic peanut oral immunotherapy
Number of subjects: 0
Study 35338860 — intervention group
Group type: COMPARATOR
Intervention: Oral immunotherapy and placebo
Number of subjects: 0
Study 36174096 — intervention group
Group type: EXPERIMENTAL
Intervention: PARADIES intervention (combined cognitive behavioural therapy with case management)
Number of subjects: 236
Study 36174096 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 236
Study 36174096 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 236
Study 33646267 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-directed intervention (in-home assessment, educational resources, communication with primary care team, telephone follow-up)
Number of subjects: 361
Study 33646267 — intervention group
Group type: COMPARATOR
Intervention: Control group (educational materials via mail)
Number of subjects: 361
Study 35435430 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing retention counseling
Number of subjects: 0
Study 36178574 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypoxic exposure for 4 weeks
Number of subjects: 9
Study 36178574 — intervention group
Group type: COMPARATOR
Intervention: Sea level exposure for 4 weeks
Number of subjects: 9
Study 34966711 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and physical training
Number of subjects: 144
Study 34966711 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture and physical training
Number of subjects: 144
Study 34966711 — intervention group
Group type: COMPARATOR
Intervention: Physical training
Number of subjects: 144
Study 32911868 — intervention group
Group type: EXPERIMENTAL
Intervention: User fee exemption cards
Number of subjects: 1652
Study 34714130 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g dried plum
Number of subjects: 66
Study 34714130 — intervention group
Group type: COMPARATOR
Intervention: Control (0 g dried plum)
Number of subjects: 66
Study 33584665 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (1 × 10^10 CFU Lactobacillus acidophilus DDS‐1 or 1 × 10^10 CFU Bifidobacterium animalis subsp. lactis UABla‐12)
Number of subjects: 58
Study 33584665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 36202391 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed tree nuts (30 g/d for 4 weeks)
Number of subjects: 79
Study 36202391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 33586003 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvia officinalis (SO) mouth rinse
Number of subjects: 88
Study 33586003 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS) mouth rinse
Number of subjects: 88
Study 33308469 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV‐19 vaccine
Number of subjects: 0
Study 33308469 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35641232 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine sulfate liposomal injection (VSLI) at 2.25 mg/m2
Number of subjects: 10
Study 35641232 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine sulfate liposomal injection (VSLI) with bendamustine and rituximab (BR)
Number of subjects: 10
Study 35641232 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine sulfate liposomal injection (VSLI)
Number of subjects: 10
Study 34823572 — intervention group
Group type: EXPERIMENTAL
Intervention: Prism adaptation treatment (twice-daily for two weeks)
Number of subjects: 31
Study 34823572 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 31
Study 34823572 — intervention group
Group type: EXPERIMENTAL
Intervention: Prism adaptation treatment
Number of subjects: 31
Study 35667713 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) for 8 weeks
Number of subjects: 0
Study 35667713 — intervention group
Group type: COMPARATOR
Intervention: Standard physical activity recommendations (Control)
Number of subjects: 0
Study 32658496 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐intensive feedback condition
Number of subjects: 368
Study 32658496 — intervention group
Group type: COMPARATOR
Intervention: Low‐intensive monitoring of progress (control condition)
Number of subjects: 368
Study 35250329 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐ and manual massage (SMM) on the plantar surface of the dominant leg
Number of subjects: 17
Study 35250329 — intervention group
Group type: COMPARATOR
Intervention: Control (non‐dominant leg, no SMM)
Number of subjects: 17
Study 32753447 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet plus conventional therapy (cinacalcet strategy)
Number of subjects: 0
Study 32753447 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (standard strategy)
Number of subjects: 0
Study 34991145 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms presentation in patients with tumors 10 cm or smaller
Number of subjects: 419
Study 34991145 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms presentation in patients with tumors larger than 10 cm to 15 cm
Number of subjects: 419
Study 34991145 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms presentation in patients with tumors larger than 15 cm
Number of subjects: 419
Study 34991145 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall symptom presentation
Number of subjects: 419
Study 34991145 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of symptoms with recurrence or survival
Number of subjects: 419
Study 32867707 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors
Number of subjects: 18
Study 34867291 — intervention group
Group type: EXPERIMENTAL
Intervention: CCT with active tDCS
Number of subjects: 46
Study 34867291 — intervention group
Group type: COMPARATOR
Intervention: CCT with sham tDCS
Number of subjects: 46
Study 34867291 — intervention group
Group type: COMPARATOR
Intervention: Watching educational videos with sham tDCS
Number of subjects: 46
Study 34910186 — intervention group
Group type: EXPERIMENTAL
Intervention: ShipShape study participants (n=147)
Number of subjects: 225
Study 34910186 — intervention group
Group type: COMPARATOR
Intervention: Non-enrolled SMs (n=38)
Number of subjects: 225
Study 34910186 — intervention group
Group type: COMPARATOR
Intervention: Navy HRBS respondents (n=164)
Number of subjects: 225
Study 34425883 — intervention group
Group type: EXPERIMENTAL
Intervention: Varoglutamstat (PQ912)
Number of subjects: 0
Study 34425883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32498073 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological challenges to suppress the HPA axis prior to stress exposure
Number of subjects: 0
Study 32498073 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological challenges to suppress the SNS prior to stress exposure
Number of subjects: 0
Study 32498073 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (baseline activation of SNS or HPA observed)
Number of subjects: 0
Study 35212573 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline depression and anxiety
Number of subjects: 518
Study 35212573 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline sleep disturbance
Number of subjects: 518
Study 35212573 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary symptom severity
Number of subjects: 518
Study 35212573 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline depression, anxiety, sleep disturbance, and physical function measures
Number of subjects: 518
Study 32991033 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors (ACEi)
Number of subjects: 252
Study 32991033 — intervention group
Group type: COMPARATOR
Intervention: No ACEi
Number of subjects: 252
Study 35655728 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracoscopy-assisted rib internal fixation
Number of subjects: 100
Study 35655728 — intervention group
Group type: COMPARATOR
Intervention: Traditional open reduction and internal fixation
Number of subjects: 100
Study 33811049 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Brief Intervention (ABI)
Number of subjects: 180
Study 33811049 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 180
Study 32066536 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous reslizumab 110 mg
Number of subjects: 468
Study 32066536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 468
Study 34260265 — intervention group
Group type: EXPERIMENTAL
Intervention: CMB305 with atezolizumab (experimental arm)
Number of subjects: 89
Study 34260265 — intervention group
Group type: COMPARATOR
Intervention: Atezolizumab alone (control arm)
Number of subjects: 89
Study 33877678 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus reuteri LRE02 and Lactobacillus rhamnosus LR04)
Number of subjects: 0
Study 36094625 — intervention group
Group type: EXPERIMENTAL
Intervention: Shunt Occlusion (SO)
Number of subjects: 40
Study 36094625 — intervention group
Group type: COMPARATOR
Intervention: Standard Medical Treatment (SMT)
Number of subjects: 40
Study 34146343 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant therapy (optimally effective)
Number of subjects: 2201
Study 34146343 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant therapy (improvement-type model)
Number of subjects: 2201
Study 34146343 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant therapy (adjusted for treatment discontinuation, remission-type model)
Number of subjects: 2201
Study 34146343 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant therapy (adjusted for treatment discontinuation, improvement-type model)
Number of subjects: 2201
Study 34146343 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 2201
Study 32623182 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine + nab-paclitaxel for 2 months then FOLFIRI.3 for 2 months (Arm A)
Number of subjects: 127
Study 32623182 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine + nab-paclitaxel alone until progression (Arm B)
Number of subjects: 127
Study 35466623 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse Tenzel flap
Number of subjects: 60
Study 35466623 — intervention group
Group type: COMPARATOR
Intervention: Cutler Beard flap
Number of subjects: 60
Study 32297486 — intervention group
Group type: EXPERIMENTAL
Intervention: brexpiprazole 1 mg/day, increased to 2 mg/day by week 4, up to 4 mg/day according to CGI-I criteria
Number of subjects: 200
Study 32297486 — intervention group
Group type: EXPERIMENTAL
Intervention: brexpiprazole
Number of subjects: 200
Study 35830641 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (1000 U/kg) administered intravenously within 26 hours after birth and at 2, 3, 4, and 7 days of age
Number of subjects: 501
Study 35830641 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) administered intravenously within 26 hours after birth and at 2, 3, 4, and 7 days of age
Number of subjects: 501
Study 35830641 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 501
Study 35830641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 501
Study 32430340 — intervention group
Group type: EXPERIMENTAL
Intervention: YAG laser peripheral iridotomy (LPI)
Number of subjects: 875
Study 32430340 — intervention group
Group type: COMPARATOR
Intervention: Control (fellow eye without LPI)
Number of subjects: 875
Study 32077353 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy decisions under assumed ideal conditions
Number of subjects: 607
Study 32077353 — intervention group
Group type: COMPARATOR
Intervention: Endovascular therapy decisions under current local resources
Number of subjects: 607
Study 34999737 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral THC
Number of subjects: 169
Study 34999737 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional near-infrared spectroscopy (fNIRS)
Number of subjects: 169
Study 34999737 — intervention group
Group type: COMPARATOR
Intervention: Drug Recognition Evaluator-conducted expanded field sobriety examination
Number of subjects: 169
Study 36053616 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wound infusion of local anaesthetic (bupivacaine) for the first 72 hours along with systemic opioid analgesia (catheter group)
Number of subjects: 30
Study 36053616 — intervention group
Group type: COMPARATOR
Intervention: Only systemic opioid analgesia (opioid group)
Number of subjects: 30
Study 36053616 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 32379666 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure applied to five acupressure points on the arms and shoulders, for six weeks, three days per week
Number of subjects: 50
Study 32379666 — intervention group
Group type: COMPARATOR
Intervention: Control group (no acupressure)
Number of subjects: 50
Study 36002844 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavour School programme (experimental group)
Number of subjects: 400
Study 36002844 — intervention group
Group type: COMPARATOR
Intervention: No intervention with normal school teaching (control group)
Number of subjects: 400
Study 33796948 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (6 months)
Number of subjects: 37
Study 33796948 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 37
Study 32667564 — intervention group
Group type: EXPERIMENTAL
Intervention: Women affected by the earthquake
Number of subjects: 0
Study 32667564 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender as a social determinant
Number of subjects: 0
Study 33388765 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator (SIM) group
Number of subjects: 58
Study 33388765 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) group
Number of subjects: 58
Study 32213300 — intervention group
Group type: EXPERIMENTAL
Intervention: Attractive food items
Number of subjects: 172
Study 32213300 — intervention group
Group type: EXPERIMENTAL
Intervention: Convenient food items
Number of subjects: 172
Study 32213300 — intervention group
Group type: COMPARATOR
Intervention: Type of diagnostic group (ADHD vs. non-ADHD)
Number of subjects: 172
Study 34398809 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) experience
Number of subjects: 64
Study 34398809 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 64
Study 32243865 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol (1 μg/kg per min, IV infusion, can be increased to a maximum of 20 μg/kg per min)
Number of subjects: 151
Study 32243865 — intervention group
Group type: COMPARATOR
Intervention: Control (conventional sepsis therapy)
Number of subjects: 151
Study 32243865 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol
Number of subjects: 151
Study 32243865 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 151
Study 35057451 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention with app and activity tracker for 3 months
Number of subjects: 650
Study 35057451 — intervention group
Group type: COMPARATOR
Intervention: Brief advice about diet and exercise
Number of subjects: 650
Study 33419426 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotoner® arthritis gloves (23-32 mmHg pressure)
Number of subjects: 206
Study 33419426 — intervention group
Group type: COMPARATOR
Intervention: Loose-fitting placebo gloves (providing no/minimal pressure)
Number of subjects: 206
Study 35113614 — intervention group
Group type: EXPERIMENTAL
Intervention: Porchlight Project intervention providing training to volunteers for dementia capable support
Number of subjects: 0
Study 32210538 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid modified, irinotecan and gene co-loaded lipid-polymer hybrid nanocarriers (HA-I/D-LPNs)
Number of subjects: 0
Study 34860481 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral phenylephrine 1.0%-ketorolac 0.3% (P/K)
Number of subjects: 56
Study 34860481 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine
Number of subjects: 56
Study 33089315 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocellular AML
Number of subjects: 25
Study 33089315 — intervention group
Group type: COMPARATOR
Intervention: Nonhypocellular AML
Number of subjects: 25
Study 32343623 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic interval training
Number of subjects: 9
Study 32343623 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity continuous exercise
Number of subjects: 9
Study 34033934 — intervention group
Group type: EXPERIMENTAL
Intervention: ICG-PDT + PIMD
Number of subjects: 48
Study 34033934 — intervention group
Group type: COMPARATOR
Intervention: PIMD
Number of subjects: 48
Study 34033934 — intervention group
Group type: EXPERIMENTAL
Intervention: ICG-PDT
Number of subjects: 48
Study 34033934 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study 35854764 — intervention group
Group type: EXPERIMENTAL
Intervention: New nursing team management mode
Number of subjects: 100
Study 35854764 — intervention group
Group type: COMPARATOR
Intervention: Traditional nursing management
Number of subjects: 100
Study 34157613 — intervention group
Group type: EXPERIMENTAL
Intervention: BioNTech (Germany)
Number of subjects: 1243
Study 34157613 — intervention group
Group type: EXPERIMENTAL
Intervention: Pfizer (U.S.)
Number of subjects: 1243
Study 34157613 — intervention group
Group type: COMPARATOR
Intervention: General animus toward the other foreign country
Number of subjects: 1243